149 related articles for article (PubMed ID: 37428874)
1. Compliance with yellow fever and measles vaccines in the revaccination program post-hematopoietic cell transplantation.
de Almeida Testa LH; Simione AJ; Dos Santos ACF; Colturato I; Barbieri F; de Souza MP; Colturato VR; Machado CM
Transpl Infect Dis; 2023 Aug; 25(4):e14098. PubMed ID: 37428874
[TBL] [Abstract][Full Text] [Related]
2. Use of live viral vaccines after HCT: Still a lot to learn.
Sabaini PMDS; Machado CM
Transpl Infect Dis; 2023 Apr; 25(2):e14044. PubMed ID: 36864672
[TBL] [Abstract][Full Text] [Related]
3. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?
Michel R; Berger F; Ravelonarivo J; Dussart P; Dia M; Nacher M; Rogier S; Moua D; Sarr FD; Diop OM; Sall AA; Baril L
Vaccine; 2015 May; 33(20):2301-6. PubMed ID: 25843268
[TBL] [Abstract][Full Text] [Related]
4. Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina.
Vizzotti C; Harris JB; Aquino A; Rancaño C; Biscayart C; Bonaventura R; Pontoriero A; Baumeister E; Freire MC; Magariños M; Duarte B; Grant G; Reef S; Laven J; Wannemuehler KA; Alvarez AMR; Staples JE
BMC Infect Dis; 2023 Mar; 23(1):165. PubMed ID: 36932346
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau.
Fisker AB; Ravn H; Rodrigues A; Østergaard MD; Bale C; Benn CS; Aaby P
Vaccine; 2014 Jan; 32(5):598-605. PubMed ID: 24325827
[TBL] [Abstract][Full Text] [Related]
6. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
[TBL] [Abstract][Full Text] [Related]
7. Immunity and Vaccination Against Measles, Mumps, and Rubella in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Kawamura K; Wada H; Nakasone H; Akahoshi Y; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Gomyo A; Tamaki M; Kusuda M; Kameda K; Sato M; Tanihara A; Kimura SI; Kako S; Kanda Y
Transplant Cell Ther; 2021 May; 27(5):436.e1-436.e8. PubMed ID: 33775586
[TBL] [Abstract][Full Text] [Related]
8. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
[TBL] [Abstract][Full Text] [Related]
9. Intervene before leaving: clustered lot quality assurance sampling to monitor vaccination coverage at health district level before the end of a yellow fever and measles vaccination campaign in Sierra Leone in 2009.
Pezzoli L; Conteh I; Kamara W; Gacic-Dobo M; Ronveaux O; Perea WA; Lewis RF
BMC Public Health; 2012 Jun; 12():415. PubMed ID: 22676225
[TBL] [Abstract][Full Text] [Related]
10. Successful restoration of protective immunity against measles, mumps, and rubella following MMR vaccination in adult hematopoietic cell transplant recipients.
Lin RY; Anderson AD; Morris MI; Raja M; Komanduri KV; Camargo JF
Transpl Infect Dis; 2023 Apr; 25(2):e14043. PubMed ID: 36880572
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Immunity against Measles, Mumps, Rubella, and Varicella Zoster in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
Yoshida S; Fujii N; Kamoi C; Kitamura W; Fujiwara H; Asada N; Nishimori H; Fujii K; Matsuoka KI; Maeda Y
Acta Med Okayama; 2022 Jun; 76(3):247-253. PubMed ID: 35790354
[TBL] [Abstract][Full Text] [Related]
12. Differences between coverage of yellow fever vaccine and the first dose of measles-containing vaccine: A desk review of global data sources.
Adrien N; Hyde TB; Gacic-Dobo M; Hombach J; Krishnaswamy A; Lambach P
Vaccine; 2019 Jul; 37(32):4511-4517. PubMed ID: 31266670
[TBL] [Abstract][Full Text] [Related]
13. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
[TBL] [Abstract][Full Text] [Related]
15. An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT.
Haynes AS; Curtis DJ; Campbell K; Giller RH; Quinones RR; Verneris MR; Abzug MJ
Transplant Cell Ther; 2021 Apr; 27(4):317-326. PubMed ID: 33836875
[TBL] [Abstract][Full Text] [Related]
16. Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant.
Desjardins M; Mitre X; Sherman AC; Walsh SR; Cheng MP; Kanjilal S; Ho VT; Baden LR; Issa NC
Open Forum Infect Dis; 2021 Dec; 8(12):ofab504. PubMed ID: 34909436
[TBL] [Abstract][Full Text] [Related]
17. Live (vaccines) from New York.
Forlenza CJ; Small TN
Bone Marrow Transplant; 2013 Jun; 48(6):749-54. PubMed ID: 22890288
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogenic Hematopoietic Cell Transplantation.
Bögeholz J; Russkamp NF; Wilk CM; Gourri E; Haralambieva E; Schanz U; Mueller NJ; Manz MG; Müller AMS
Biol Blood Marrow Transplant; 2020 Mar; 26(3):581-592. PubMed ID: 31682977
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
Martin C; Domingo C; Bottieau E; Buonfrate D; De Wit S; Van Laethem Y; Dauby N
Clin Microbiol Infect; 2021 Jul; 27(7):958-967. PubMed ID: 33813107
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children.
Idoko OT; Mohammed N; Ansah P; Hodgson A; Tapia MD; Sow SO; Chowdhury PR; Niedrig M; Saathoff E; Kampmann B
Expert Rev Vaccines; 2019 Aug; 18(8):867-875. PubMed ID: 31269829
[No Abstract] [Full Text] [Related]
[Next] [New Search]
